# Characteristics and Outcomes of Multisystem Inflammatory Syndrome in Children: A Multicenter, Retrospective, Observational Cohort Study

# 2 in Children:3 in Mexico

4 Nadia González-García<sup>1,</sup> Marco Antonio Yamazaki-Nakashimada<sup>2</sup>, Horacio

5 Márquez-González<sup>1</sup>, Guadalupe Miranda-Novales<sup>3</sup>, Gonzalo Antonio Neme

6 Díaz<sup>4</sup>, Sandhi Anel Prado Duran<sup>5</sup>, Antonio Luévanos Velázquez<sup>6</sup>, Maria F.

Castilla-Peon<sup>7\*</sup>, \*, Miguel Alejandro Sánchez Duran<sup>2</sup> Martha Patricia Márquez
 Aguirre 2, Miguel Angel Villasis-Keever<sup>3</sup>, Ranferi Aragón Nogales<sup>8</sup>, Carlos Núñez

Aguirre 2, Miguel Angel Villasis-Keever <sup>3</sup>, Ranferi Aragón Nogales <sup>8</sup>, Carlos Núñez
 Enríquez <sup>8</sup>, Maria Elena Martinez Bustamante <sup>9</sup>, Carlos Aguilar Argüello <sup>4</sup>, Jesús

10 Ramírez de los Santos <sup>10</sup>, Alejandra Pérez Barrera <sup>4</sup>, Lourdes Anais Palacios

11 Cantú<sup>11</sup>, Jesús Membrila Mondragón<sup>11</sup>, Paloma Vizcarra Alvarado<sup>6</sup>, Rodolfo

- 12 Norberto Jiménez Juárez <sup>12</sup>, Víctor Olivar López <sup>1</sup> and Adrián López Chávez <sup>1</sup>
- 13
- 14 1Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
- 15 <sup>2</sup>National Institute of Pediatrics (Mexico), Mexico City, Mexico
- <sup>16</sup> <sup>3</sup>Analysis and Synthesis of Evidence Research Unit, XXI Century National
- 17 Medical Center, Mexican Social Security Institute, Mexico City, Mexico
- 18 <sup>4</sup>Hospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico
- <sup>5</sup>HGZ No 15, Mexican Social Security Institutte, Tamaulipas, Mexico
- <sup>6</sup>Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara,
- 21 Mexico
- 22 <sup>7</sup>Hospital Psiquiatrico Infantil Juan N Navarro, Mexico City, Mexico
- 23 <sup>8</sup>XXI Century National Medical Center, Mexican Social Security Institute,
- 24 Mexico City, Mexico
- <sup>25</sup> <sup>9</sup>Department of Pediatric Infectious Diseases, Centro Médico Nacional 20 de
- 26 Noviembre (CMN), Mexico City, Mexico
- <sup>10</sup>Department of Infectious Diseases, Hospital del Niño Dr. Rodolfo Nieto
- 28 Padrón, Villahermosa, Mexico
- 29 <sup>11</sup>HGR No 270, Mexican Social Security Institute, Tamaulipas, Mexico
- 30 <sup>12</sup>Infectious diseases, Hospital Infantil de Mexico Federico Gomez, Mexico City,
- 31 Mexico
- 32
- 33

#### 34 Abstract

#### 35

36 Multisystem inflammatory syndrome in children temporally associated with coronavirus 37 disease 2019 (MIS-C), a novel hyperinflammatory condition secondary to severe acute 38 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with severe 39 outcomes such as coronary artery aneurysm and death. This multicenter, retrospective, 40 observational cohort study including eight centers in Mexico, aimed to describe the clinical 41 characteristics and outcomes of patients with MIS-C. Patient data were evaluated using 42 latent class analysis to categorize patients into three phenotypes: toxic shock syndrome-like 43 (TSSL)-MIS-C, Kawasaki disease-like (KDL)-MIS-C, and nonspecific MIS-C (NS-MIS-C). Risk factors for adverse outcomes were estimated using multilevel mixed-effects 44 45 logistic regression. The study included 239 patients with MIS-C, including 61 (26%), 70 (29%), and 108 (45%) patients in the TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C groups, 46 47 respectively. Fifty-four percent of the patients were admitted to the intensive care unit, and 48 42%, 78%, and 41% received intravenous immunoglobulin, systemic glucocorticoids, and 49 anticoagulants, respectively. Coronary artery dilatation and aneurysm were found in 5.7% 50 and 13.2% of the patients, respectively. The rate of mortality due to SARS-CoV-2-related 51 factors was 4.6%. Delay of  $\geq 10$  days in hospital admission was associated with coronary 52 artery aneurysm or dilatation (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2–2.0). 53 Age  $\geq$  10 years (OR 5.6, 95% CI 1.4–2.04), severe underlying condition (OR 9.3, 95% CI 54 2.8-31.0), platelet count <  $150,000/\text{mm}^3$  (OR 4.2, 95% CI 1.2–14.7), international 55 normalized ratio > 1.2 at admission (OR 3.8, 95% CI 1.05–13.9), and serum ferritin 56 concentration > 1500 mg/dL (OR 52, 95% CI 5.9–463) were risk factors for death. 57 58 **Keywords:** coronary aneurysm; coronavirus disease 2019; Mexico; multicenter study; 59 multisystem inflammatory disease; pediatric; severe acute respiratory syndrome 60 coronavirus 2;

- 61
- 62

#### 63 1 Introduction

64 65 Multisystem Inflammatory Syndrome in Children (MIS-C), temporally associated with 66 coronavirus disease 2019 (COVID-19) also known as pediatric multisystem inflammatory 67 syndrome, is a novel hyperinflammatory condition secondary to severe acute respiratory 68 syndrome coronavirus 2 (SARS-CoV-2) infection and shares features with Kawasaki 69 disease, toxic shock syndrome, and acute COVID-19. MIS-C was first described in April 70 2020 in the United Kingdom, followed by case reports in other countries. (1,2)

71

72 The clinical case definition of MIS-C varies slightly among different health 73 agencies. (2-4) Clinical features include fever, gastrointestinal symptoms, conjunctival 74 injection, rash, and elevated inflammatory markers. (5)Potential complications include 75 shock, multi-organ failure, and myocardial and coronary artery involvement similar to 76 those observed in Kawasaki disease. (6-8) Many patients with MIS-C have evidence of 77 SARS-CoV-2 infection within several weeks before disease onset. (9-11) The estimated 78 incidence of MIS-C is 3-5 per 10,000 among individuals aged <21 years who are infected 79 with SARS-CoV2. Studies in ethnically diverse countries reported a higher incidence of

80 MIS-C in Hispanic and Afro-descendant individuals, emphasizing the need to characterize 81 the clinical spectrum of MIS-C in specific populations. (12)

82

83 Several reports have suggested the existence of different MIS-C phenotypes, 84 including the Kawasaki disease-like (KDL)-MIS-C, the toxic shock syndrome-like (TSSL)-85 MIS-C, as well as the nonspecific MIS-C with predominantly acute respiratory 86 (NS-MIS-C). Differentiating MIS-C from acute COVID-19 and other involvement 87 hyperinflammatory conditions can be challenging for healthcare providers. The treatment 88 approach for MIS-C includes intravenous immunoglobulin (IVIG), systemic 89 glucocorticoids, and anti-inflammatory biological agents; the efficacy of these treatments 90 relies on the timely diagnosis of MIS-C.

91

Despite its low prevalence, MIS-C is a serious life-threatening condition. Therefore,
 this study aimed to examine the clinical characteristics and outcomes of KDL-MIS-C,
 TSSL-MIS-C, and NS-MIS-C among patients with MIS-C in eight tertiary-care pediatric
 centers in Mexico. We also performed exploratory analyses to identify factors associated
 with coronary artery abnormalities and death.

97

### 98 **2. Materials and Methods**

### 99 2.1 Study design

This was a multicenter, retrospective, observational cohort study including patients
diagnosed with MIS-C in one of the eight participating pediatric tertiary care centers in
Mexico. Four centers were located in Mexico City: Federico Gómez Mexico Children's
Hospital, National Institute of Pediatrics, Siglo XXI Medical Center's Pediatrics Hospital,
and. Guadalajara Civil Hospital was located in Guadalajara, Jalisco; Villa Hermosa
Children's Hospital was located in Villa Hermosa, Tabasco, and one investigator collected
data on cases from the state of Tamaulipas.

100

The study was approved by Federico Gómez Mexico Children's Hospital
Institutional Review Board (approval no. HIM-2022-015) and the local ethics review board
of the remaining participating centers.

- Probable MIS-C cases were identified by the review of medical records of patients
  admitted to the emergency room, intensive care unit (ICU), or the general hospital ward for
  COVID-19. Patient files were evaluated to determine if they met the MIS-C case definition
  of the Centers for Disease Control and Prevention (Chart 1). (2)
- 116

Local investigators at participating centers collected data from the medical records using REDCap (Research Electronic Data Capture) software hosted at Federico Gómez Mexico Children's Hospital. Personal identifiers were kept confidential at participating centers and were not registered in the general database. Data were retrieved from REDCap, inconsistencies and missing data were corrected through direct communication with local investigators, units of measurement were unified, and variables were converted as necessary.

124

125 The worst value measured within the first three days of hospitalization was obtained 126 for laboratory parameters with more than one measurement. Life support measures 127 (respiratory support and vasopressor utilization) and the use of IVIG, systemic 128 glucocorticoids, and anticoagulant therapy were documented as primary therapeutic 129 interventions. Outcomes of interest were admission, length of ICU stay and hospitalization, 130 need for invasive mechanical ventilation, vasopressor support, myocardial depression (left 131 ventricular ejection fraction < 55%), coronary aneurysm (coronary artery diameter z-score 132  $\geq$  2.5) and coronary artery dilatation (diameter z-score >2–<2.5) on the echocardiographic 133 evaluation performed during hospitalization, and in-hospital mortality. 134 135 In the present study, severe respiratory involvement was defined as the presence of 136 infiltrates on chest X-ray or computed tomography plus the need for oxygen administration 137 with a non-rebreathing mask or a device with higher oxygen concentration. Additionally, 138 "gastrointestinal symptoms" was defined as the presence of at least one of the following: 139 abdominal pain, diarrhea, and emesis. Severe underlying conditions included cancer and 140 other immunosuppressive states, neuromuscular disability, chronic respiratory diseases 141 except for asthma, congenital cardiac disorders, and chronic kidney failure. 142 143 2.2 Statistical analysis

Descriptive analyses were conducted using STATA v.14.0 (StataCorp, Houston, TX,
USA). Categorical variables were reported as frequencies, and continuous variables were
reported as medians with interquartile ranges.

148

144

149 In the present study, we utilized LCA to classify 239 patients into the TSSL-PIMS, 150 KDL-PIMS, and U-PIM groups, congruent with the phenotypes identified in previous 151 studies. (13–15) LCA is a probabilistic modeling algorithm that allows clustering cases by 152 associating indicator categorical variables. Three-class LCA was conducted using the R software package "poLCA" with 100 iterations to identify the clusters. The fit of each 153 154 model was assessed using the Bayesian information criterion score. Indicator variables used 155 in the final LCA model were the 20 features of Kawasaki disease, KDL-MIS-C, NS-MIS-156 C-TS, and TSSL-MIS-C. (Table 1, Suppl Chart 1).

157

Potential heterogeneity among the participating centers was addressed by determining 95% confidence intervals (CIs) of the frequencies of measured outcomes using random-effects meta-analysis. Odds ratios (ORs) with 95% CIs of pooled data were calculated using clustered-robust standard error adjustment. ORs adjusted for the participating centers were calculated using multilevel mixed-effects logistic regression.

163

## 164 **3. Results**

165

Of the 264 identified patients, 6, 11, and 8 were excluded due to duplicate records,
lack of evidence on multi-organ involvement, and lack of evidence of previous SARSCoV-2 infection, respectively. Tables 1 and 2 summarize the clinical characteristics and
outcomes of the remaining 239 patients included in the final analysis.

170

171 LCA indicated that 61 (26%), 70 (29%), and 108 (45%) of the patients exhibited the 172 clinical profiles of TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C, respectively (Table 1). The 173 median age was higher in the TSSL-MIS-C group than in the overall cohort (11[IQR:7.1-174 14.4] versus 7.8[IQR:2.6-13.2] years). Duration of clinical symptoms before diagnosis was 175 significantly shorter in the KDL-MIS-C group than in the other two clinical groups (p < p176 0.001). Additionally, the frequency of virologic positivity for acute SARS-CoV-2 infection 177 was lower (p < 0.001) and the frequency of serologic positivity tended to be higher (p =178 (0.08) in the KDL-MIS-C group than in the other two clinical groups. Only four (5.7%)179 children in the KDL-MIS-C group had a severe underlying condition, while it was present 180 in 15(24.6%) and 22(20.4%) of the TSSL-MIS-C and NS-MIS-C, respectively. The levels of plasma inflammatory markers were highest in the TSSL-MIS-C group compared with 181 182 the other two clinical groups.

183

184 **Table 2** describes treatments and outcomes in the total study population and the 185 three clinical groups. IVIG and systemic glucocorticoids were administered in 172 (42%) 186 and 187 (78.2%) of the patients, respectively; both treatments were more frequently (93%) 187 and 91%) administered to patients in the KDL-MIS-C group. Anticoagulant therapy was 188 prescribed in 99 (41.4%) of the whole cohort and administered more frequently (60%) in 189 the TSSL-MIS-C group. Oxygen supplementation and vasopressor support were required in 190 143 (59%) and 92 (39%) of the whole cohort, respectively. Left ventricular ejection 191 fraction was below 55% in 31% of the patients, and coronary artery dilatation and 192 aneurysm were observed in 9 (5.7%) and 21(13.2%) of the patients in whom an 193 echocardiogram was performed, respectively. The median in-hospital stay for the whole 194 cohort was eight days (IQR: 5-13), and about half (54.4%) of the patients were admitted to 195 the ICU. There were 13 in-hospital deaths (5.4%), including eight patients with severe 196 underlying conditions and two who died from causes unrelated to SARS-COV-2 infection. 197 Most deaths (69%) occurred in the TSSL-MIS-C group, whereas no deaths occurred in the 198 KDL-MIS-C group.

199

Hematologic, neurologic, gastrointestinal, mucocutaneous, and renal dysfunction were frequently observed, with variability in their frequencies among the clinical groups. Prolonged coagulation time based on international normalized ratio, low platelet count, gastrointestinal symptoms, and acute renal injury were more frequent in the TSSL-MIS-C group (61%, 67%, 90%, and 33% of the patients, respectively) than in the other clinical groups.

206

207 Coronary aneurysm or dilatation occurred in 27 (11.3%) patients. (2) After
208 adjustment for cluster effect, symptom duration > 10 days before hospital admission was
209 the only factor significantly associated with coronary artery abnormalities (OR 1.6, 95% CI
210 1.2–2.0). (Table 3).

211

212Risk factors for death were age  $\geq 10$  years (OR 5.6, 95% CI 1.4–2.04), presence of213at least one underlying condition (OR 5.3, 95% CI 1.5–18.4), severe underlying condition214such as cancer (OR 9.3, 95% CI 2.8–31.0), platelet count < 150,000/mm³ (OR 4.2, 95% CI</td>2151.2–14.7), international normalized ratio > 1.2 at admission (OR 3.8, 95% CI 1.05–13.9),216and serum ferritin concentration > 1500 mg/dL (OR 52, 95% CI 5.9–463) (Table 4).217

The patient population was not homogeneous among the eight participating centers. Heterogeneity was high for almost all calculated treatment and outcome frequencies, and I<sup>2</sup>, a measure of heterogeneity, was 50% for most of the factors. Accordingly, association measures were adjusted for the center effect. A significant cluster effect of the reporting center was demonstrated for every evaluated factor in **Tables 3** and **4**. Disaggregated data collected from the five centers with more included cases are presented in **Supplementary Tables 1** and **2**.

225

### **4. Discussion**

MIS-C, a recently characterized clinical presentation secondary to SARS-CoV-2 infection,
is closely associated with Kawasaki disease and toxic shock syndrome. In the present study,
we aimed to summarize the clinical characteristics and outcomes of patients with MIS-C
treated in eight pediatric tertiary care centers across Mexico. Our analyses reveal that these
patients share several similarities with previous case series while exhibiting some
differences and illustrate the presence of high heterogeneity in disease presentation and
outcomes among the participating centers.

234

235 It is relevant and essential to examine the clinical characteristics, disease 236 management, and outcomes of MIS-C due to the potentially severe consequences such as 237 death (16–18), damage to coronary arteries, and the toll on healthcare resources necessary 238 for its management. The present cohort's mortality rate was 4.6%, which exhibited high 239 heterogeneity across the centers, ranging from 0% to 13.5%. Similarly, the rate of coronary 240 artery abnormalities, which was 18.9% in the overall cohort, ranged from 0% to 56.3% 241 across the participating centers. Published systematic reviews estimate mortality and a rate 242 of coronary artery abnormalities ranging from 0% to 4% and from 11.6% to 21.7%, 243 respectively, in patients with MIS-C, according to the systematic reviews (19–23). In the 244 present study, coronary artery abnormalities were observed in all three clinical groups, with 245 no significant difference in frequency among the groups.

Among the factors that might explain the high heterogeneity in outcomes between the centers included in our study and the previously published case series are (i) a wide spectrum of clinical presentation in the presence of relatively nonspecific diagnostic criteria that are currently used for MIS-C, (ii) variations in ethnicity and prevalence of comorbid conditions, and (iii) variations in access, diagnostic paths, and therapeutic interventions across different healthcare systems.

252

253 Attempts have been made to classify cases according to their predominant clinical 254 characteristics to address the lack of specific diagnostic criteria and, thus, phenotype 255 heterogeneity. In the present study, we utilized LCA to classify 239 patients into the TSSL-256 MIS-C, KDL-MIS-C, and U-PIM groups, congruent with the phenotypes identified in 257 previous studies (13–15) In the present study, patient age was different among the clinical 258 groups; additionally, the frequency of virologic positivity was lower, and the frequency of 259 serologic positivity was higher in the KDL-MIS-C group than in the other two clinical groups, suggesting different underlying pathologic mechanisms at play. Multiple pathologic 260 261 mechanisms have been shown to be altered in MIS-C, including the possible involvement of superantigens and autoantibodies. (24) The levels of plasma inflammatory markers were 262 263 highest in the TSSL-MIS-C group. Additionally, the rate of life support measures and

mortality rate were highest in this group, as expected. The vagueness of the current clinical
 criteria for MIS-C might be partially responsible for the wide variation in the rate of these
 three clinical phenotypes reported by each center, suggesting a lack of clarity among
 physicians for the threshold of clinical manifestations that eventually leads to the diagnosis
 of MIS-C (Supplementary Table 1).

- Demographic and preexisting medical conditions of patients in different published
  series and clinical groups widely vary, likely accounting for some of the heterogeneity
  observed in outcomes.
- 274 In the present study, 34.7% of the cohort had underlying conditions, which was 275 higher than that reported by Radia et al. and Antúnez et al. (25) In the present cohort, 276 severe underlying conditions were present in 17.5% of the patients varying from 3.6% to 277 23.1% across the participating centers. In addition, the frequency of patients with 278 cancer/immunosuppressive disorders or neuromuscular conditions was four to tenfold. In 279 contrast, the observed frequency of obesity (15.9%) was not as high as that reported by 280 other studies. (26) Notably, 9 of the 13 deaths in the present cohort had a severe underlying 281 condition, and the mortality was highest in the center with the highest rate of patients with 282 severe underlying conditions and the highest proportion of patients with TSSL-MIS-C. 283 These findings suggest that the high rate of severe underlying conditions might explain the 284 relatively high mortality observed in the present cohort.
- 285

269

286 Although the centers included in the present study are tertiary care reference 287 hospitals, they belong to different healthcare systems with different protocols for service 288 delivery and different resources for the management of patients during the COVID-19 289 pandemic; the difference in frequencies of IVIG utilization (from 45% to 94%) might be a 290 reflection of this aspect. In addition, there is evidence of an association between delayed 291 access to health services and worst outcomes, which might explain differences in risk for 292 bad outcomes across different geographic locations(27)Of note, the only factor that was 293 significantly associated with the development of coronary artery abnormalities after 294 adjustment for center effect was a delay of  $\geq 10$  days in hospital admission after the onset of 295 symptoms, a factor likely influenced by socioeconomic and geographic factors. 296

297 Factors associated with mortality were age  $\geq 10$  years, severe underlying condition, 298 thrombocytopenia, hyperferritinemia, and toxic shock syndrome phenotype. A study in a 299 larger cohort might reveal an association with other factors, such as IVIG use and 300 coagulopathy. Abrams et al. reported that older age, non-Hispanic black ethnicity, disease 301 onset before June 1, 2020, and high levels of serum D-dimer, troponin, atrial natriuretic 302 peptide, C-reactive protein, ferritin, and interleukin-6 were associated with ICU admission 303 in patients with MIS-C. The authors also reported abdominal pain and shortness of breath 304 as clinical findings at hospitalization admission predicting subsequent ICU admission. (28) 305

According to most systematic reviews, myocarditis is the most frequent
complication observed in patients with MIS-C; however, it was not examined in the present
study due to the lack of a standardized definition among the participating centers. However,
left ventricular ejection fraction, which was below 55% in 31% of the cohort, might be
considered a proxy for this outcome. In addition, we did not evaluate socioeconomic status,

ethnicity, and the levels of D-dimer, troponin-B, natriuretic peptide, or interleukin-6, whichwere assessed in previous studies.

313

314 In conclusion, death was an infrequent outcome in patients with MIS-C, occurring 315 mainly in older patients with severe underlying conditions, whereas coronary aneurysms 316 were primarily associated with delayed treatment. Extrapolation of the frequency of 317 observed outcomes to the general population might not be valid due to the high frequency 318 of comorbid conditions and the heterogeneity of participating centers. The causal 319 association of risk factors with adverse outcomes should be further analyzed in longitudinal 320 studies with sufficient statistical power to adjust for multiple confounding factors found in 321 the present cohort.

322

## 323 **5. Conflict of Interest**

324

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

328

## **6. Author Contributions**

MFCP, NGG, and HMG contributed to the conception and design of the study. HMG
coordinated interinstitutional collaboration. NGG organized the database. MFCP and NGG
performed the statistical analysis. MAYN, NGG, and MFCP wrote the first draft of the
manuscript. All authors contributed to data gathering and manuscript revision and read and
approved the submitted version.

336

# **337 7. Funding**

338

The authors declare that this study received funding from Hospital Infantil de Mexico
Federico Gómez. The funder was not involved in the study design, collection, analysis, or
interpretation of data.

342 343

# 343 8. Acknowledgments344

We acknowledge the authorities of participating centers for the facilities to perform thisstudy.

- 347
- 348

# 349 9. Data Availability Statement

- 350
- 351 Datasets are available on request to NGG (nadiag.him@gmail.com)352

## **10. References**

 Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 – Induced Kawasaki-Like Hyperin fl anmatory Syndrome□: A Novel COVID Phenotype in Children. Pediatrics. 2021;146(2):1–5.

357 358	2.	HAN Archive - 00432   Health Alert Network (HAN) [Internet]. [cited 2021 Dec 13]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp
359 360 361	3.	Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory syndrome temporally associated with Cov-19. Royal College of Paediatrics and Child Health. 2020;1–6.
362 363 364	4.	Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–88.
365 366 367	5.	Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–88.
368 369 370 371	6.	Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID- 19. JAMA - Journal of the American Medical Association. 2021;325(11):1074–87.
372 373 374	7.	Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal of Medicine. 2021;385(1):23–34.
375 376 377 378	8.	Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4(9):669–77.
379 380 381	9.	Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020;395(10237):1607–8.
382 383 384	10.	Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. New England Journal of Medicine. 2020;383(4):347–58.
385 386 387 388	11.	Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during the COVID-19 Pandemic. JAMA Pediatr. 2021;175(8):837–45.
389 390 391 392 393	12.	Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open [Internet]. 2021 Jun 1 [cited 2021 Dec 13];4(6):e2116420–e2116420. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861

394       1         395       396         397       398         399       399	3.	Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020. The Lancet Regional Health - Europe [Internet]. 2021 Apr 1 [cited 2021 Dec 13];3. Available from: http://www.thelancet.com/article/S2666776221000521/fulltext
400 14 401 402 403	4.	Godfred-Cato S, Abrams JY, Balachandran N, Jaggi P, Jones K, Rostad CA, et al. Distinguishing Multisystem Inflammatory Syndrome in Children from COVID-19, Kawasaki Disease and Toxic Shock Syndrome. Pediatric Infectious Disease Journal. 2022 Apr 1;41(4):315–23.
404 1: 405 406 407 408	5.	Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data- driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine [Internet]. 2021;40:09–10. Available from: https://doi.org/10.1016/j.eclinm.2021.101112
409 10 410 411 412 413 414	6.	Laverty M, Salvadori M, Squires SG, Ahmed M, Eisenbeis L, Lee S, et al. Multisystem inflammatory syndrome in children in Canada. Canada Communicable Disease Report [Internet]. 2021 Nov 10;47(11):461–5. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/reports- publications/canada-communicable-disease-report-ccdr/monthly-issue/2021- 47/issue-11-november-2021/ccdrv47i11a03-eng.pdf
415 1 416 417 418	7.	Baradaran A, Malek A, Moazzen N, Shaye ZA. COVID-19 associated multisystem inflammatory syndrome: A systematic review and meta-analysis. Vol. 19, Iranian Journal of Allergy, Asthma and Immunology. Tehran University of Medical Sciences; 2020. p. 570–88.
419 1 420 421 422 423	8.	Ruvinsky S, Voto C, Roel M, Fustiñana A, Veliz N, Brizuela M, et al. Multisystem Inflammatory Syndrome Temporally Related to COVID-19 in Children From Latin America and the Caribbean Region: A Systematic Review With a Meta-Analysis of Data From Regional Surveillance Systems. Vol. 10, Front Pediatr. Frontiers Media S.A.; 2022. p. 871765.
424 19 425 426	9.	Hoste L, Paemel R van, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr [Internet]. 2021;180(7):2019–34. Available from: https://doi.org/10.1007/s00431-021-03993-5
427 20 428 429 430	0.	Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Vol. 38, Paediatr Respir Rev. W.B. Saunders Ltd; 2021. p. 51–7.
431 2 432 433	.1.	Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta- analysis. Pediatr Pulmonol. 2021 May 1;56(5):837–48.

434 435 436 437	22.	Godfred-Cato S, Abrams JY, Balachandran N, Jaggi P, Jones K, Rostad CA, et al. Distinguishing Multisystem Inflammatory Syndrome in Children from COVID-19, Kawasaki Disease and Toxic Shock Syndrome. Pediatric Infectious Disease Journal. 2022 Apr 1;41(4):315–23.
438 439 440 441	23.	Santos MO, Gonçalves LC, Silva PAN, Moreira ALE, Ito CRM, Peixoto FAO, et al. Multisystem inflammatory syndrome (MIS-C): a systematic review and meta- analysis of clinical characteristics, treatment, and outcomes. Vol. 98, Jornal de Pediatria. Elsevier Editora Ltda; 2022. p. 338–49.
442 443 444	24.	Porritt RA, Binek A, Paschold L, Rivas MN, McArdle A, Yonker LM, et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. Journal of Clinical Investigation. 2021;131(20).
445 446 447 448	25.	Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2021;40(1):e1–6.
449 450 451	26.	Miller A, Zambrano L, Yousaf AR, Abrams JY, Meng L, Wu MJ. Multisystem Infalmmatory Syndrome in Children- United States, February 2020-July 2021. Clin Infect Dis. 2022;75(1):e1165–75.
452 453 454 455	27.	Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during the COVID-19 Pandemic. JAMA Pediatr. 2021 Aug 1;175(8):837–45.
456 457 458 459	28.	Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May 1;5(5):323–31.
460		

461 462

Chart 1. Case definition criteria for M	hart 1. Case definition criteria for MIS-C						
1. Fever							
2. Elevation of inflammation markers	At least one of the following: • C-Reactive Protein (CRP) >5mg/L • Procalcitonin > 0.15 ng/ml • Ferritin > 300 mcg/L • Fibrinogen > 400 mg/dl • D-Dimer >560 ng/ml • Neutrophils > 7500 cells/mcl • Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl • Albumin < 3 g/dl						
3. At least two systems involved	<ul> <li>3.1 Cardiovascular. At least one of the following:</li> <li>Required vasoactive drug</li> <li>Left ventricular ejection fraction &lt; 55%</li> </ul>						
	<ul> <li>3.2 Respiratory. At least one of the following:</li> <li>3.3 Supplementary oxygen with non-rebreathing mask or higher oxygen concentration device.</li> <li>Oxygen saturation &lt;90%</li> <li>Pulmonary infiltrates in chest X-Ray or Computed Tomography</li> </ul>						
	<ul> <li>3.4 Neurologic. At least one of the following:</li> <li>3.5 Glasgow score &lt; 14 if not sedated</li> <li>Meningismus</li> <li>Seizures</li> </ul>						
	<ul> <li>3.4 Hematologic. At least one of the following:</li> <li>Platelets &lt; 150 000 cells/mcl</li> <li>INR &gt; 1.2 sec</li> </ul>						
	<ul> <li>3.5 Gastrointestinal. At least one of the following:</li> <li>Abdominal pain</li> <li>Vomit</li> <li>Diarrhea</li> <li>Alanine aminotransferase (ALT) &gt; 90 U/L</li> </ul>						
	<ul> <li>3.6 Mucocuteneous. At least one of the following:</li> <li>Rash</li> <li>Extremity edema</li> <li>Desquamation</li> <li>Mucosal inflammation</li> <li>Conjunctivitis</li> <li>3.7. Renal</li> </ul>						
	Creatinine > twice the upper limit of the reference range for age						
<ul><li>4. Hospitalization</li><li>5. No alternative diagnosis</li></ul>	<ul> <li>No positive blood culture during the first 48 hours in the hospital</li> <li>In uncertain cases, complete file review and consensus by an expert panel.</li> </ul>						
<ol> <li>Present or recent infection by SARS COV-2</li> <li><sup>1</sup>Reverse transcriptase polymerase chair</li> </ol>	<ul> <li>At least one of the following <ul> <li>Positive RT-PCR<sup>1</sup> for SARS-CoV-2</li> <li>Positive serology for SARS-CoV-2</li> <li>Contact with a confirmed positive COVID-19 case in the last four weeks.</li> </ul> </li> </ul>						

Tabl.1. Clinical presentation of cases with MIS-C							
	Total population (N=239) <sup>1</sup>	Group 1 Toxic shock syndrome like (N=61)	Group 2 Kawasaki like (N=70)	Group 3 Nonspenspecific (N=108 )	P value <sup>2</sup>		
Female sex -no. (%)	103 (43.1%)	29 (47.5%)	30 (43.5%)	44 (40.7%)	0.68		
Age median (IQR)	7.8(2.6-13.2)	11.0 (7.1-14.4)	6.8 (2.4-10.5)	6.2 (1.9-13.4)	<0.001		
<1 y	30 (12.6%)	2 (6.7%)	6 (20%)	22 (73.3%)			
1-4 y	57 (23.9%)	7 (12.3%)	26 (45.6%)	24 (42.1%)			
5-9 y	54 (22.6%)	14 (25.9%)	19 (35.2%)	21 (38.9%)			
10-14 y	67 (28.03%)	28 (41.8%)	17 (25.4%)	22 (32.8%)			
15-18 v	31 (13.0%)	10 (32.3%)	2 (6.5%)	19 (61.3%)			
Days with symptoms before admission	6 (4-9)	7 (4-8)	4 (2-6)	7 (4-10)	< 0.001		
SARS-CoV2 infection evidence							
Positive RT- PCR test	105/182 (57.7%)	40/57 (70%)	16/54 (29.6%)	49/71 (69%)	<0.001		
Positive rapid antigen test	46/129 (35.7%)	14/34 (41.2%)	9/44 (20%)	23/51 (45.1%)	0.03		
Positive RT-PCR or rapid antigen test	130/213 (61.0%)	47/60 (78%)	23/65 (35.4%)	60/88 (68.2%)	< 0.001		
Positive serology	114/160 (71.3%)	24/37 (64.9%)	43/52 (82.7%)	47/71 (66.2%)	0.08		
Previous comorbidities				, (			
Obesity (BMI $>$ 95th percentile)	38 (15.9%)	5 (8,6%)	12 ( (17.6%)	21 (19.4%)	0.17		
Respiratory	11 (4.6%)	3 (6.7%)	2 (10.5%)	6 (9.8%)	0.76		
Neuromuscular	14 (15 9%)	5 (11.1%)	3 (15.8%)	6 (9.8%)	0.69		
Cardiovascular	6 (2,5%)	1(2,2%)	0	5(8,2%)	0.25		
Cancer	16 (6.7%)	7 (15.6%)	0	9(14.8%)	0.18		
	3 (1 3%)	2 (4 4%)	0	1(1.6%)	0.74		
At least one underlying condition	83 (34,7%)	24 (39.3%)	17 (24.3%)	42 (38.9%)	0.09		
Severe underlying condition	41 (17 5%)	15 (24 6%)	4 (5 7%)	22 (20 4%)	0.004		
Clinical presentation	11 (17.570)	15 (21.070)	1 (3.770)	22 (20.170)	0.004		
Rash	98 (41%)	30 (49.2%)	49 (70%)	19 (17.6%)	< 0.001		
Conjunctivitis	118 (49.4%)	32 (52,5%)	59 (84,3%)	27 (25%)	<0.001		
Diarrhea	80 (33,5%)	25 (41.0%)	23 (32.9%)	32 (29.6%)	0.31		
Emesis	86 (36.0%)	29 (47.5%)	29 (41.4%)	28 (25.9%)	0.01		
Abdominal pain	91 (38.1%)	43 (70 5%)	33 (47.1%)	15 (13.9%)	<0.001		
Rhinorrhea	57(23.8%)	22 (36 1%)	21 (30%)	14 (13%)	0.001		
Respiratory dysfunction	150 (62.8%)	54 (88 5%)	25 (35 7%)	71 (65 7%)	<0.001		
Anosmia/Dysgeusia	11 (4 6%)	5 (8 2%)	23 (33.770)	4(3.7%)	0.33		
Arthralgias/Myalgias	48 (20.1%)	13 (21.3%)	2(2.5%) 22 (31.4%)	13 (12 0%)	0.007		
I aboratory findings	40 (20.170)	15 (21.570)	22 (31.470)	15 (12.070)	0.007		
Neutrophil count x10 <sup>6</sup> cells/mcl	81(42-136)	65(17-122)	95(63-149)	77(37-125)	0.02		
Neutrophilia (>7500 cells/mcl)	130/238 (54 6%)	30 (49 2%)	46/69 (66 7%)	54 (50%)	0.02		
Neutropenia (<1000 cells/mcl)	22 /239 (9 2%)	7 (11 5%)	2 (2 9%)	13 (12%)	0.00		
I vmphocyte count $x10^6$ cells/mcl	14(06-26)	08(04-17)	13(0.9-2.2)	18(09-34)	<0.07		
Lymphoeyte count x10 cens/mer	165/237 (69.6%)	44 (73 3%)	56/69 (81.2%)	65 (60 2%)	0.01		
Platelets x 10 <sup>3</sup> cells/mcl	173 (96-315)	104 (64-165)	193 (99-329)	216(148-365)	<0.01		
$\frac{1}{2} \frac{1}{2} \frac{1}$	93/239 (38.9%)	41 (67 2%)	25 (35 7%)	27 (25%)	<0.001		
Fibringen mg/dl	427 (298-559)	508(348-617)	401(306-549)	391 (256-531)	0.24		
Fibringgen \ 400 mg/dl	$\frac{427}{2}(2)(553)$	39/58 (67.2%)	24/51(47.1%)	$\frac{371}{230-331}$	0.24		
Ferritin mcg/I	557 (304-1209)	828 (508-1956)	/37 (213-793)	530 (252-1209)	0.10 <b>-0.001</b>		
Ferritin 300 mg/dl	1/1/101(75/1%)	50/54 (92.6%)	30/50 (66 1%)	55/78 (70.5%)	0.001		
Ferritin > 1500 mg/dl	$\frac{144}{191} (15.4\%)$	14/54 (25.0%)	2/50 (3.4%)	16/78(20.5%)	0.001		
D Dimor ng/ml	22(191(10.770))	14/34(23.370)	2/39(3.470)	10/78(20.3%)	<0.001		
D-Dimer $1g/111$ D. Dimer 560ng/ml (0.56 ng/L)	2.2(1-3) 104/210(88.6%)	4.3 (1.7-9.2)	2.1 (1.0-3.6)	82/04 (87 2%)	0.178		
C reportive protein (0.30 llg/L)	194/219(00.0%)	33/30(94.0%)	37/07(03.1%)	02/74(07.2%)	0.1/0		
C-reactive protein (mg/L)	200/225 (28 00/ )	13 (7-31.3)	30.1 (14.0-1/9.3)	22.3 (7.3-80.9)	0.85		
C-reactive protein > 5mg/L	200/225(88.9%)	30/30 (89.3%)	02/08 (91.2%)	$\frac{68}{101} (8/.1\%)$	0./1		
Procalcitonin ng/mi	0.85 (0.14-3.6)	1.9 (0.3-4.8)	0.5 (0.0-2.5)	0.3(0.1-2.3)	0.005		
$\frac{\text{Procalcitonin} > 0.15 \text{ng/ml}}{\text{Albumin} < 2 \text{ s/dl}}$	120/1/1 (/3./%)	49/33 (89.1%)	21/41 (65.9%)	50/75(66.7%)	0.005		
	155/222 (59.9%)	51/01 (83.0%)	40/00 (00.0%)	42/93 (44.2%)	<0.001		

<sup>1</sup>N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. <sup>2</sup> One-sided Fisher exact test/ Mann-Whitney test for comparison between groups 1, 2, and 3. <sup>a</sup> Lymphopenia: <2 years: <4000, 2-3 years: <3000, >4 years: <1500 cells/mcl

Table 2. Treatment and outcomes of cases with MIS-C										
	Total sample (N=239) <sup>1</sup>	OR (IC 95% <sup>2</sup> )	Between centers heterogeneity $I^2(p)$	Group 1 Toxic shock like (N=61)	Group 2 Kawasaki like (N=70)	Group 3 Nonspecific (N=108)	P value <sup>3</sup>			
Treatment – no. (%)										
Intravenous immune globulin	172 (42.0%)	0.76(0.58-0.94)	70.3%(<0.001)	49(80%)	65 (93%)	58 (53.7%)	<0.001			
Systemic steroids	187 (78.2%)	0.81 (0.67-0.94)	54.1% (<0.001)	52(85%)	64(91%)	71(66%)	<0.001			
Anticoagulation therapy	99 (41.4%)	0.35 (0.10-0.60)	96.4% (<0.001)	42(69%)	16(23%)	41(38%)	< 0.001			
Ventilatory support needed - no (%)										
Any oxygen supplementation	143(59.8%)	0.54(0.34-0.72)	94.5% (<0.001)	57(93.4%)	30(43%)	56(52%)	<0.001			
Non-invasive mechanical ventilation	14 (5.9%)	0.07 (0.01-0.13)	62.5% (0.0)	8(13%)	0	6(5.6%)	0.006			
Invasive mechanical ventilation	57 (23.9%)	0.19 (0.04-0.33)	91.7% (>0.001)	41(67.2)	0	16(15%)	< 0.001			
Any infiltrates in chest Rx or CT <sup>4</sup>	127/224 (56.7%)	0.46 (0.22-0.71)	94.1% (<0.001)	46(75%)	19(27%)	62(57%)	< 0.001			
Severe respiratory involvment <sup>5</sup>	82/239 (34.3%)	0.32 (0.19-0.44)	75.7 %(<0.001)	36(59%)	16(22%)	30(27%)	< 0.001			
Cardiovascular involvement	,				,					
LVEF <sup>5</sup> <55%	61/194 (31.4%)	0.43(0.31-0.55)	47.6% (0.13)	25(41%)	7(10%)	29(27%)	< 0.001			
LVEF<45%	20/194 (10.3%	0.14 (0.06-0.22)	37.8%(0.19)	7(12%)	1(1.4%)	12(11%)	0.02			
LVEF <35%	10/194 (5.2%)	0.04 (0.01-0.11)	-	3(5%)	0	7(7%)	0.05			
Coronary aneurysm ( $z > 2.5$ )	21/159 (13.2%)	0.19 (0.06-0.32)	61% (0.04)	6(10%)	6 (9%)	9(8%)	0.87			
Coronary dilatation (z: 2 -2.5)	9/159 (5.7%)	0.12 (0.04-0.21)	0% (0.48)	1(2%)	4(6%)	4(4%)	0.47			
Vasopressor support – no (%)	92/235 (39.2%)	0.35 (0.10-0.6)	96.4% (<0.001)	48(79%)	4(6%)	40 (37%)	< 0.001			
Hematologic involvement										
INR > 1.2	104/233 (44.6%)	0.46 (0.30-0.62)	82.8 %(<0.001)	37(61%)	31(44%)	36(33%)	0.002			
Platelets count <150 000 cell/mcl	93 (38.9%)	0.40 (0.31-0.48)	41.2% (0.12)	41(67%)	25 (36%)	27(25%)	<0.001			
Neurologic involvement	16 (6.7%)	0.06 (0.03-0.09)	0% (0.74)	3(5%)	4(6%)	9(8.3%)	0.43			
Gastrointestinal involvement	175 (73%)	0.74 (0.60-0.89)	89.2% (<0.001)	55(90%)	57(80%)	63(58%)	< 0.001			
Alanine Aminotransferase > 90 U/L	53/203 (26.1%)	0.24 (0.15-0.33)	52.2% (0.06)	19(31%)	14(20%)	20(19%)	0.08			
Mucocutaneous involvement	192 (80.3%)	0.83 (0.72-0.93)	80.9 %(<0.001)	52(81%)	70(100%)	70(69%)	<0.001			
Acute Kidney Injury <sup>6</sup>	35/226 (15.5%)	0.14(0.09-0.20)	33.9% (0.20)	20(33%)	6 (9%)	9(8%)	<0.001			
ICU <sup>7</sup> admission	130 (54.4%)	0.43 (0.17-0.69)	-	52(85%)	42(60%)	36(33%)	< 0.001			
Length of ICU stay, days (n=129)	4 (2-7)	-	-	5(3-8)	3(2-6)	4(2-7)	0.34			
Length of Hospital stay days	8 (5-13)	-	-	10(6-17)	8(6-12)	8(4-13	0.10			
Any cause in-hospital deaths	13 (5.4%)	0.05 (0.01-0.09)	40.1 % (0.17)	9(15%)	0	4(4%)	<0.001			
Died from SARS COV-2	11 (4.6%)	0.04 (0.0-0.08)	54.5% (0.09)	8(13%)	0	3(3%)	<0.001			
<sup>1</sup> N was used to calculate proportions if no	<sup>1</sup> N was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. <sup>2</sup> Exact confidence									

intervals by random effects metaanalisis of eight centers data. This analysis excludes centers with frequencies=0% and 100%, which explains the difference in point estimate with the first column. <sup>3</sup> Exact Fisher Kruskal Kruskal Wallis as suitable for comparison between groups 2 and 3. <sup>4</sup>Rx: chest X-ray, CT: Computed tomography. <sup>5</sup>LVEF= Left ventricular ejection fraction. <sup>6</sup> Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. <sup>7</sup> ICU: intensive care unit.

Table 3. Coronary artery aneurism or dilatation associated factors.								
	Frequency in the aneurism/ dilatation	Unadjusted OR (95% CI) <sup>1</sup>	p-value	OR adjusted for center <sup>2</sup>	p-value			
	group N=27 (%)							
Sex (male)	19/27 (70.4%)	2.20 (0.99-4.9)	0.05	1.71 (0.63-4.58)	0.29			
Age>=10 years	5/27(18.5%)	0.31 (0.05-2.04)	0.22	0.55 (0.17-1.80)	0.32			
>=10 days with symptoms before	10/25 (40%)	4.16 (2.61-6.23)	<0.001	1.62 (1.19-2.04)	<0.001			
admission								
Positive SARS-COV-2 RT-PCR or	12/20 (60%)	0.70 (0.13-3.73)	0.67	1.11 (0.31-3.96)	0.87			
rapid antigen test								
Positive SARS-COV-2 serology	16/20 (80%)	2.58 (0.77-8.64)	0.125	1.45 (0.36-5.89)	0.60			
Obesity (BMI > 95th percentile)	16/20 (80%)	1.04 (0.53-2.04)	0.92	1.40 (0.37-5.37)	0.63			
Rash	9/27 (33%)	0.49 (0.10-2.29)	0.36	0.69 (0.25-1.91)	0.48			
Conjunctivitis	17/27 (63.0%)	1.5 (0.33-6.92)	0.60	1.82 (0.57-5.77)	0.31			
Gastrointestinal	16/27 (59.3%)	0.39 (0.10-1.49)	0.17	0.70 (0.22-2.15)	0.54			
Severe respiratory dysfunction	11/27 (40.74%)	1.53 (0.63-3.71)	0.35	1.56 (0.59-4.18)	0.37			
Arthralgias/Myalgias	2/27 (4.41%)	0.21 (0.05-0.94)	0.04	0.13 (0.02-0.67)	0.015			
Mucocutaneous involvement	13/27 (48.15%)	0.35 (0.17-0.70)	0.003	0.74 (0.25-2.17)	0.59			
Neutrophilia (>7500 cells/mcl)	19/27 (70.37%)	2.13 (0.82-5.58)	0.12	1.87 (0.67-5.22)	0.23			
Lymphopenia <sup>3</sup>	15/27 (55.56%)	0.52 (0.20-1.31)	0.17	0.40 (0.15-1.10)	0.08			
Platelets count <150 000 cell/mcl	7/27 (25.93%)	0.48 (0.17-1.40)	0.18	0.48 (0.16-1.37)	0.17			
Fibrinogen> 400 mg/dl	11/21 (52.38%)	0.68 (0.26-1.75)	0.42	0.86 (0.31-2.37)	0.77			
Ferritin> 300 mg/dl	18/20 (90%)	4.39 (0.81-23.89)	0.09	4.50 (0.90-22.5)	0.07			
D- Dimer> 560ng/ml (0.56 ng/L)	24/26 (92.3%)	1.64 (0.41-6.47)	0.48	0.97 (0.17-5.66)	0.98			
C-reactive protein $> 5 \text{mg/L}$	26/27 (96.3%)	2.41 (0.47-12.4)	0.29	2.68 (0.28-25.31)	0.39			
Procalcitonin > 0.15ng/ml	15/23 (65.2%)	0.45 (0.27-0.76)	0.003	0.84 (0.23-3.00)	0.75			
Albumin< 3g/dl	20/27 (74.07%)	1.83 (0.72-4.62)	0.20	1.62 (0.57-4.63)	0.90			
INR > 1.2	14/27 (51.85%)	1.37 (0.54-3.54)	0.50	2.45 (0.86-7.00)	0.093			
LVEF <sup>4</sup> <55%	8 /25 (32%)	1.25 (0.30-5.1)	0.76	1.49 (0.50-4.47)	0.45			
Alanine Aminotransferase > 90 U/L	4/25 (16%)	0.53 (0.19-1.43)	0.21	0.97 (0.26-3.70)	0.97			
Intravenous immune globulin	27/27 (100%)	-	-	-	-			
Systemic steroids	21/27 (77.78%)	0.9 (0.16-4.93)	0.90	0.96 (0.27-3.3)	0.95			
Group 1((TSS-like)	7/27 (25.9%)	1 (reference)	-	1 (reference)	-			
Group 2 (Kawasaki-like)	9/27 (33.3%)	1.14 (0.29-4.45)	0.85	0.66 (0.17-2.58)	0.55			
Group 3 (Unespecific presentation)	11/27 (40.7%)	1.25 (0.25-6.15)	0.78	0.59 (0.15-2.31)	0.45			
<sup>1</sup> Clustered robust standard error adjustment <sup>2</sup> OR adjusted for center with multilevel mixed-effects logistic regression								

<sup>3</sup>Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl. <sup>4</sup>LVEF=Left ventricular ejection fraction.

Table 4. Characteristics of deaths and associated	conditions		
	Deaths (N=13)	р <sup>1</sup>	OR (IC95%) <sup>2</sup>
Female sex -no. (%)	4	0.26	0.57 (0.17-1.96)
Age-median (IQR)	14.4 (10.6-15.3)	0.02	-
<1 y	2	-	-
1-4 y	1		
5-9 y	0		
10-14 y	6		
15-18 y	4		
Age>=10 years	10	0.008	5.64 (1.43-22.22)
Days of symptoms before admission	4 (2-5)	0.4	
More than 10 days since symptom onset	3	0.39	1.53 (0.36-6.47)
Positive RT- PCR test	8/10	0.11	3.13 (0.76-12.81)
Positive rapid antigen test	2/6	0.49	0.80 (0.17-3.69)
Positive RT-PCR or rapid antigen test	8/12	0.47	1.42 (0.38-5.28)
Positive SARS-CoV-2 serology	3/4	0.67	0.81 (0.05-13.62)
Obesity (BMI $> 95$ th percentile)	0	0.09	-
Respiratory	1	0.58	1.08 (0.11-10.82
Neuromuscular	3	0.06	3.73 (0.73-19.19)
Cardiovascular	0	0.63	-
Cancer	4	0.016	6.3 (1.3-30.6)
Immunosuppression	1	0.20	6.99 (0.41-119.11)
End-stage chronic renal disease	1	0.20	1.69 (0.15-18.7)
At least one underlying condition	9	0.01	5.3 (1.5-18.4)
Severe underlying condition	8	<0.001	9.3 (2.8-31.0)
On palliative care	1	-	-
Lymphocyte count $x10^6$ cells/mcl -median (IOR)	0.6 (0.3-1.4)	0.01	_
Lymphopenia <sup>a</sup>	10	0.40	1.4 (0.4-5.5)
Platelets x 10 <sup>3</sup> cells/mcl	94 (46-191)	0.03	-
Platelets $< 150 \times 10^3$ cells/mcl median (IOR)	9	0.023	4.2 (1.2-14.7)
Fibrinogen, mg/dl	94 (46-191)	0.89	-
Fibringen> 400 mg/dl	6/8	0.24	2.48 (0.47-13.15
Ferritin, mcg/-L median (IOR)	3619 (2108-4752)	<0.001	
Ferritin >300	9/9	0.04	-
Ferritin >1500	8/9	<0.001	52 (5.9-463)
Intravenous immune globulin	8	0.28	0.34 (0.08-1.44)
Systemic steroids	11	0.43	1.28 (0.25-6.61)
Anticoagulation therapy	7	0.25	1.52 (0.45- 5.15)
Coronary aneurysm (z score $> 2.5$ )	0/2	0.75	-
Coronary dilatation (z score $>2 - <2.5$ )	0/2	0.89	_
INR > 1.2	9	0.06	3.8 (1.05-13.9)
ICU <sup>3</sup> admission	11	0.02	6.5 (1.14-37.11)
Group 1(TSS-like)	9	0.001	1 (reference)
Group 2) (Kawasaki like)	0		-
Group 3 (Unespecific presentation)	4		0.15 (0.03-0.66)
1Comparison with surviving cases with one tailed e	xact Fisher test or Man	n-Whitney I	J test. <sup>2</sup> OR adjusted by
center with multilevel mixed effects logistic regress	$ion.^3$ ICU= Intensive ca	are unit. <sup>a</sup> Ly	mphopenia: <2 years:

<4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl

Table Suppl.1 Clinical presentation of cases with MIS-C for the five centers with more included cases.							
	Total population	Center 1	Center 2	Center 3	Center 4	Center 5	
	$(N=239)^{1}$	(N=75)	(N=52)	(N=28)	(N=45)	(N=30)	
Female sex -no. (%)	103 (43.1%)	39 (52%)	21 (40.4%)	6 (21.4%)	17 (38.6%)	15 (50%)	
Age - median (IQR)	7.8(2.6-13.2)	11.1 (5.7-15.7)	10.6 (6.6-14.6)	7.0 (2.6-9.6)	2.4 (0.7-7.6)	3.6 (1.3-10.2)	
<1 y	30 (12.6%)	5(6.7%)	3 (5.8%)	1 (3.6%)	15 (13.3%)	5 (16.7%)	
1-4 y	57 (23.9%)	11 (14.7%)	8 (15.4%)	8 (28.6%)	14 (31.1%)	12 (40%)	
5-9 у	54 (22.6%)	14 (18.7%)	12 (23.1%)	13 (46.4%)	8 (17.8%)	5 (16.7%)	
10-14 y	67 (28.03%)	25 (33.3%)	19 (36.5%)	6 (21.4%)	8 (17.8%)	7 (23.3%)	
15-18 у	31 (13.0%)	20 (26.7%)	10 (19.2%)	0	0	1 (3.3%)	
Days with symptoms before	6 (4-9)	7 (4-7)	5 (3-9)	6 (4-7)	8 (5-14)	3.5 (2-6)	
admission	0(17)	7(17)	5 (5 7)	0(17)			
SARS-COV2 testing No. (%)	r			i			
Positive RT- PCR test	105/182 (57.7%)	57/71 (80.3%)	13/33 (39.4%)	5/18 (27.8%)	17/39 (43.6%)	6/12 (50%)	
Positive rapid antigen test	46/129 (35.7%)	20/36 (55.6%)	9/34 (26.5%)	1/11 (9.1%)	7/23 (30.4%)	5/19 (26.3%)	
Positive RT-PCR or rapid	130/213 (61.0%)	71/75 (94.7%)	32/52(61.5%)	4/28 (14.3%)	11/22 (50%)	7/27 (25.9%)	
antigen test							
Positive SARS-COV-2	114/160 (71.3%)	25/59 (42.4%)	16/19 (82.6%)	18/21 (85.7%)	32/33 (97.0%)	19/23 (82.6%)	
serology	. ,	. ,					
Underlying medical conditions No. (%)			0 (17 40()	4 (14 20()	4 (0.00()	4 (12 20()	
Obesity (BMI > 95th	38 (15.9%)	14 (18.7%)	8 (15.4%)	4 (14.3%)	4 (8.9%)	4 (13.3%)	
percentile)	11 (1 69()	5 (6 70()	2 (2 00()	0	2 (4 40/)	1 (2 20/)	
Respiratory	11 (4.6%)	5 (6.7%)	2 (3.9%)	0	2 (4.4%)	1 (3.3%)	
Neuromuscular	14 (15.9%)	6 (8%)	4 (7.7%)	1 (3.6 %)	2 (4.4%)	1 (3.3%)	
Cardiovascular	6 (2.5%)	3 (4%)	2 (3.9%)	0	1 (2.2%	0	
Cancer	16 (6.7%)	7 (9.3%)	3 (5.8%)	0	4 (8.9%)	0	
Immunosuppression	3 (1.3%)	2 (2.7%)	1 (1.9%)	0	4 (8.9%)	15 (50%)	
At least one underlying	83 (34,7%)	34 (45.3%)	16 (30.8%)	1(3.6%)	15 (33.3%)	15 (50%)	
condition		( ,			0.01=0000	. (10-1)	
Severe underlying	41 (17.5%)	16 (21.3%)	12 (23.1%)	1 (3.6%)	8 (17.8%)	3 (10%)	
condition			10 (24 (24)	15(60.50()	2 (6 70()	00 (66 50)	
Rash	98 (41%)	36 (48%)	18 (34.6%)	17(60.7%)	3 (6.7%)	20 (66.7%)	
Conjunctivitis	118 (49.4%)	30 (40%)	39 (75%)	17 (60.7%)	6 (13.3%)	21 (70%)	
Diarrhea	80 (33.5%)	33 (44%)	11 (21.2%)	13 (46.4%)	10 (22.2%)	12 (40%)	
Emesis	86 (36.0%)	36 (48%)	15 (28.9%)	22 (78.6%)	1 (2.2%)	11 (36.7%)	
Abdominal pain	91 (38.1%)	38 (50.7%)	24(46.2%)	13 (46.4%)	2 (4.4%)	12 (40%)	
Rhinorrhea	57(23.8%)	24 (32%)	25 (48.1%)	0	0	8 (26.7%)	
Respiratory dysfunction	150 (62.8%)	67 (89.3%)	42 (80.8%)	8 (28.6%)	21 (46.7%)	6 (20%)	
Anosmia/Dysgeusia	11 (4.6%)	7 (9.3%)	3 (5.8%)	0	1 (2.2%)	0	
Arthralgias/Myalgias	48 (20.1%)	14 (18.7%)	17 (32.7%)	9 (32.1%)	0	7 (23.3%)	
Respiratory support with high flow	73 (30.5%)	39 (52%)	16 (30.1%)	4 (14.3%)	10 (22.2%)	4 (13.3%)	
cannula or more							
Neutrophil count x10 <sup>o</sup> cells/mcl	8.1 (4.2-13.6)	6.1 (1.7-9.1)	8.5(5.5-13.3)	11.1 (6.9-15.9)	5.6 (4.5-15.5)	9.7(5.9-15.5)	
Neutrophilia (>7500 cells/mcl)	130/238 (54.6%)	29/74 (39.2%)	33/52 (63.5%)	20/28 (71.4%)	23/45 (51.1%)	21/30 (70%)	
Neutropenia (<1000 cells/mcl)	22/239 (9.2%)	11/75 (14.7%)	3 (5.8%)	1 (3.6%)	5 (11.1%)	1 (3.3%)	
Lymphocyte count x10° cells/mcl	1.4 (0.6-2.6)	1.5 (0.6-2.4)	0.8 (0.5-1.5)	1.2 (0.7-1.8)	2.9 (1.6-4.5)	1.4(1.0-2.1)	
Lymphopenia <sup>a</sup>	165/237 (69.6%)	43//3 (58.9%)	42 (80.1%)	25 (89.3%)	22 (48.9%)	26 (86.7%)	
Platelets x 10 <sup>3</sup> cells/mcl	173 (96-315)	161 (94-236)	176 (107-249)	152 (75-386)	289 (155-533)	175 (87-340)	
Platelets < 150 x 10 <sup>°</sup> cells/mcl	93/239 (38.9%)	30/75 (40%)	20/52 (38.5%)	14/28 (50%)	11/45 (24.4%)	12/30 (40%)	
Fibrinogen, mg/dl	427 (298-559)	1284 (495-3641)	452 (326-600)	404 (313-496)	250 (197-304)	313 (226-544)	
Fibrinogen> 400 mg/dl	104/183 (56.8%)	52/75 (69.3%)	28/50 (56%)	14/27 (51.9%)	3/13 (23.08%)	4/10 (40%)	
Ferritin, mcg/L	557 (304-1209)	618 (410-1340)	629 (457-1617)	761 (246-921)	343 (184-708)	329 (166-593)	
Ferritin> 300 mg/dl	144/202 (71.3%)	53/75 (70.7%)	37/44 (84.1%)	14/19 (73.7%)	17/28 (60.7%)	17/29 (58.6%)	
D-Dimer ng/ml	2.2 (1-5)	2.6 (1.1-6.4)	2.6(1.7-5.4)	1-6(1.0-3.2)	1.6(0.6-3.9)	1.4(0.4-2.4)	
D- Dimer> 560ng/ml (0.56 ng/L)	194/219 (88.6%)	66/74 (89.2%)	48/49 (98%)	25/28 (89.3%)	27/32 (84.4%)	20/28 (71.4%)	
C-reactive protein (mg/L)	60 (17-180)	100 (43-190)	13.9 (7.1-23.14)	168 (112-293)	33.6 (13.2-190)	101 (34-209)	
C-reactive protein > 5mg/L	200/225 (88.9%)	58/63 (92.1%)	39 (76.5%)	28/28 (100%)	40/45 (88.9%)	28/30 (93.3%)	
Procalcitonin ng/ml	0.85 (0.14-3.6)	1.85 (0.5-6.23)	0.06(0.01-0.53)	2.24 (0.82-6.0)	0.40 (0.14-4.5)	0.5 (1.5-1.5)	
Procalcitonin > 0.15ng/ml	126 /171 (73.7%)	55/62 (88.7%)	14/36 (38.9%)	15/16 (93.8%)	22/32 (68.8%	13/17 (76.5%)	
Albumin< 3g/dl	133/222 (59.9%)	45/71 (63.4%)	25(51.0%)	19/28 (67.9%)	23/37 (62.2%)	16 (55.2%)	
Clinical profile							
Group 1(Kawasaki like)	61 (25.5%)	36 (48%)	15 (28.9%)	7 (25%)	2 (4.4%)	1 (3.3%)	
Group 2(TSS-like)	70 (29.3%)	2 (2.7%)	22 (42.3%)	12 (42.9%)	2 (4.4%)	27 (90%)	
Group 3 (Unespecific presentation)	108 (45.2%)	37 (49.3%)	15 (28.9%)	9(32.1%)	41 (91%)	2 (3.7%)	
'N in the column heading was used to	calculate proportions	if not otherwise spec	ified. For variables wi	ith missing data, den	ominators are reported	in each cell,	
<sup>1ympnopenna</sup> : <2 years: <4000, 2-3 years: <	< 3000, >4 years: <150	0 cells/mcl					

Table Suppl.2          Treatment and outcomes of cases with MIS-C for the five centers with more included cases.								
	Total sample(N=239) <sup>1</sup>	Center 1 (N=75)	Center 2 (N=52)	Center 3 (N=28)	Center 4 (N=45)	Center 5 (N=30)	IC 95% <sup>2</sup>	Heterogeneity I <sup>2</sup> (p)
Treatment – no. (%)								
Intravenous immune globulin	172 (71.2.0%)	34 (45.3%)	49 (94.2%)	25 (89.3%)	28 (62.2%)	28 (93%)	0.76(0.58-0.94)	70.3%(<0.001)
Systemic steroids	187 (78.2%)	53 (70.7%)	51 (98.1%)	21 (75%)	26 (57.8%)	29 (96.7%)	0.81 (0.67-0.94)	54.1 (<0.001)
Anticoagulation therapy	99 (41.4%)	47 (62.7%)	34 (65.4%)	1/ (3.6%)	14 (31.1%)	2 (6.7%)	0.35 (0.10-0.60)	96.4% (<0.001)
Ventilatory support needed - no (%)								
Any oxygen supplementation	143(59.8%)	61 (81.3%)	44 (84.6%)	15 (53.6%)	13 (28.9%)	5 (16.7%)	0.54(0.34-0.72)	94.5% (<0.001)
Non-invasive mechanical ventilation	14 (5.9%)	8 (10.7%)	5 (9.6%)	0	1 (2.2%)	0	0.07 (0.01-0.13)	62.5 (0.0)
Invasive mechanical ventilation	57 (23.9%)	34 (45.3%)	15 (28.9%)	2 (7.14%)	5 (11.11%)	1 (3.3%)	0.19 (0.04-0.33)	91.7 (>0.001)
Any infiltrates in chest Rx or CT <sup>3</sup>	127/224 (56.7%)	60/71 (84.5%)	32 (61.5%)	7 (25%)	18/34(52.9%)	6 (20%)	0.46 (0.22-0.71)	94.1% (<0.001)
Severe respiratory involvment <sup>4</sup>	82/239 (34.3%)	28 (37.3%)	30 (57.8%)	6 (21.4%)	10 (22.2%)	5 (16.7%)	0.32 (0.19-0.44)	75.7 %(<0.001)
Cardiovascular involvement - no (%)		•						
LVEF <sup>5</sup> <55%	61/194 (31.4%)	30/75 (40%)	18/37 (48.7%)	0/22 (0%)	8/27 (29.6%)	0/25 (0%)	0.43(0.31-0.55)	47.6% (0.13)
LVEF<45%	20/194 (10.3%	6/75 (8%)	6/16.2 (37%)	0	7 /27 (25.9%)	0	0.14 (0.06-0.22)	37.8%(0.19)
LVEF <35%	10/194 (5.2%)	0	3 /37 (8.1%)	0	7 /27 (25.9%)	0	0.04 (0.01-0.11)	-
Coronary aneurysm (z score > 2.5)	21/159 (13.2%)	5/75 (6.7%)	5/25 (20%)	3/15 (20%)	6/16 (37.5%)	0/25 (0%)	0.19 (0.06-0.32)	61% (0.04)
Coronary dilatation (z score >2 - <2.5)	9/159 (5.7%)	0	4/25 (16%)	1/15 (6.7%)	3/16 (18.8%)	0/25 (0%)	0.12 (0.04-0.21)	0% (0.48)
Vasopressor support – no (%)	92/235 (39.2%)	41/75 (54.7%)	20/51 (39.2%)	7/27 (25.9%)	21/44(47.7%)	1/30 (3.3%)	0.35 (0.10-0.6)	96.4% (<0.001)
Hematologic involvement								
INR > 1.2	104/233 (44.6%)	38/75 (50.7%)	22/52 (42.3%)	21/28 (75%)	7/39 (18.0%)	11/30 (36.7%)	0.46 (0.30-0.62)	82.8 %(<0.001)
Platelets count <150 000 cell/mcl	93 (38.9%)	30 (40%)	20 (38.5%)	14 (50%)	11 (24%)	12 (40%)	0.40 (0.31-0.48)	41.2% (0.12)
Neurologic involvement	16 (6.7%)	5 (6.7%)	3 (5.8%)	1 (3.6%)	5 (11.1%)	1 (3.3%)	0.06 (0.03-0.09)	0% (0.74)
Gastrointestinal involvement	175 (73%)	60 (80%)	39 (75%)	26 (92.9%)	19 (42.2%)	28 (93.3%)	0.74 (0.60-0.89)	89.2% (<0.001)
Alanine Aminotransferase (ALT) > 90 U/L	53/203 (26.1%)	21/72 (29.2%)	6/30 (20%)	3/28 (10.7%)	10/35(28.6%)	12/30 (40%)	0.24 (0.15-0.33)	52.2% (0.06)
Mucocutaneous involvement	192 (80.3%)	64 (85.3%)	43 (82.7%)	25 (89.3%)	26 (57.8%)	29 (30%)	0.83 (0.72-0.93)	80.9 (<0.001)
Acute Kidney Injury, stage 2 <sup>6</sup>	35/226 (15.5%)	13/69 (18.8%)	11/52 (21.2%)	5/28 (17.9%)	4/41 (9.8%)	2/29 (6.9%)	0.14(0.09-0.20)	33.9 (0.20)
ICU <sup>7</sup> admission	130 (54.4%)	48 (64.0%)	36 (69.2%)	7 (25%)	5 (11.1%)	30 (100%)	0.43 (0.17-0.69)	
Length of ICU stay-d (n=130)	4 (2-7)	4 (2-8)	4.5 (2-7)	4 (2-4)	4 (3-5)	3 (2-7)	-	-
Length of Hospital stay days	8 (5-13)	7 (4-13)	10 (6-16)	7.5 (5-11)	8 (5.5-16)	8.5 (7-10)	-	-
Any cause in-hospital death	13 (5.4%)	2 (2.7%)	7 (13.5%)	0	3 (6.7%)	1 (3.3%)	0.05 (0.01-0.09)	40.1 % (0.17)
Died from COVID-19	11 (4.6%)	1 (1.33%)	7(13.5%)	0	2(4,4%)	1 (3.3%)	0.04 (0.0-0.08)	54.5% (0.09)
<sup>1</sup> N in the column heading was used to calculate	e proportions if not otherwise	e specified. For variab	les with missing data	, denominators are re	ported in each cell. 2 Ex	act confidence int	ervals by random effects	metaanalisis. This
analysis excludes centers with frequencies=0%	and 100%, which explains t	he difference in point	estimate with the firs	t column. 3 Rx: chest	X-ray, CT: Computed t	omography. 4Sev	ere respiratory involvement	ent was defined as

analysis excludes centers with requencies=0% and 100%, which explains the difference in point estimate with the first column. KX: chest A-ray, CT: Computed tomography. Severe respiratory involvement was defined as oxygen requirement and infiltrates in thoracic imaging.<sup>2</sup>LVEF= Left ventricular ejection fraction. <sup>6 Acute</sup> Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age.<sup>7</sup> ICU: intensive care unit.

#### Supplementary Chart 1. Variables included in Latent Class Analysis

- . Any cardiac involvement: cardiac arrest OR any one or more of the following findings on Echo:
- Myocardial depression (left ventricular ejection fraction < 55%)
- •Coronary aneurysms (coronary artery diameter z-score  $\geq 2.5$ )
- •Dilatation (z-score >2–<2.5)
- Mitral or aortic valve insufficiency
- Myocardial infarction
- Other abnormalities reported
- 2. Gastrointestinal involvement: Vomiting or diarrhea
- 3. Gastrointestinal involvement: Abdominal pain
- 4. Respiratory failure (any one of the following):
- CPAP
- Conventional ventilation
- 5. Kawasaki features: Conjunctivitis (bilateral, bulbar, non-suppurative)
- 6. Kawasaki features: Lymphadenopathy (cervical >1.5 cm diameter)
- 7. Kawasaki features: Rash (widespread, polymorphous, not vesicular)
- 8. Kawasaki features: Lips and mucosa (red cracked lips, strawberry tongue, erythematous oral cavity)
- 9. Kawasaki features: Changes of extremities (erythema, edema of palms and soles initially)

#### 10. Any other rash

- 11. Hypotension
- 11. Albumin  $\log < 3g/dl$
- 13. Raised ALT (>82 IU/L if <1yr, >56 IU/L if <3yrs, >58 IU/L if <7yrs, >72 IU/L if <13yrs, >74 IU/L if 13-15yrs)
- 14. Raised ferritin (>300 ug/L)
- 15. Raised D-dimers (>560 ng/ml)
- 16. Confusion
- 17. Creatinine (for <4yrs ≥78 umol/L, 5-11 years ≥106 umol/L, 12-15 years ≥180 umol/L)
- 18. Platelets ( $<150 \times 10^3$  cells/mm<sup>3</sup>)
- 19. Positive SARS-CoV-2 PCR test
- 20. Positive SARS-CoV-2 serology test